

[Sofosbuvir + velpatasvir](#)

Essential medicine status

Section:

[6. Anti-infective medicines](#) [6.4. Antiviral medicines](#) [6.4.4. Antihepatitis medicines](#) [6.4.4.2. Medicines for hepatitis C](#)

[6.4.4.2.1. Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations](#)

ATC codes: [J05AP55](#)

EMLc

Indication

Chronic hepatitis C ICD11 code: [1E91.1](#)

INN

Sofosbuvir + velpatasvir

Medicine type

Chemical agent

List type

Core

Formulations

Oral > Solid > tablet: 200 mg + 50 mg (EMLc) ; 400 mg + 100 mg

Oral > Solid > granules: 150 mg + 37.5 mg in sachet (EMLc) ; 200 mg + 50 mg in sachet (EMLc)

EML status history

First added in 2017 ([TRS 1006](#))

Changed in 2019 ([TRS 1021](#))

Changed in 2021 ([TRS 1035](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

Medicines within the same pharmacological class can be used

Therapeutic alternatives limitations

Pangenotypic direct-acting antiviral combinations

Therapeutic alternatives limitations for EMLc

Pangenotypic direct-acting antiviral combinations

Patent information

Main patent is active in several jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org

Read more [about patents](#).

Wikipedia

[Sofosbuvir + velpatasvir](#)

DrugBank

[Sofosbuvir](#),

[Velpatasvir](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of sofosbuvir + velpatasvir oral granules 150 mg + 37.5 mg and 200 mg + 50 mg to the EMLc.